Frank G. Rücker

5.8k total citations · 1 hit paper
41 papers, 2.0k citations indexed

About

Frank G. Rücker is a scholar working on Hematology, Molecular Biology and Cancer Research. According to data from OpenAlex, Frank G. Rücker has authored 41 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Hematology, 24 papers in Molecular Biology and 8 papers in Cancer Research. Recurrent topics in Frank G. Rücker's work include Acute Myeloid Leukemia Research (29 papers), Chronic Myeloid Leukemia Treatments (10 papers) and Advanced biosensing and bioanalysis techniques (8 papers). Frank G. Rücker is often cited by papers focused on Acute Myeloid Leukemia Research (29 papers), Chronic Myeloid Leukemia Treatments (10 papers) and Advanced biosensing and bioanalysis techniques (8 papers). Frank G. Rücker collaborates with scholars based in Germany, United States and Austria. Frank G. Rücker's co-authors include Lars Bullinger, Konstanze Döhner, Hartmut Döhner, Richard F. Schlenk, Stefan Fröhling, Claudia Scholl, Andrea Corbacioglu, Marianne Habdank, Stephan Bohl and Arnold Ganser and has published in prestigious journals such as Science, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Frank G. Rücker

40 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations

2005 603 citations Konstanze Döhner, Richard F. Schlenk et al. Blood profile →

Peers

Countries citing papers authored by Frank G. Rücker

Since Specialization

Citations

This map shows the geographic impact of Frank G. Rücker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank G. Rücker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank G. Rücker more than expected).

Fields of papers citing papers by Frank G. Rücker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank G. Rücker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank G. Rücker. The network helps show where Frank G. Rücker may publish in the future.

Co-authorship network of co-authors of Frank G. Rücker

This figure shows the co-authorship network connecting the top 25 collaborators of Frank G. Rücker. A scholar is included among the top collaborators of Frank G. Rücker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank G. Rücker. Frank G. Rücker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	TET2 deficiency cooperates with CBFB‐MYH11 to induce acute myeloid leukaemia and represents an early leukaemogenic event 2022 ·British Journal of Haematology ·Kristian Reckzeh, Montserrat Estruch, Mina Ali, (unknown), (unknown), Kyoung‐Jae Won, Frank G. Rücker, Konstanze Döhner, Kim Theilgaard‐Mönch	2
2	A call for HoLEP: en-bloc vs. two-lobe vs. three-lobe 2021 ·World Journal of Urology ·Frank G. Rücker, Karin Lehrich, (unknown), Margit Zacharias, Sascha Ahyai, Jens Hansen	33
3	The retinoic acid receptor co-factor NRIP1 is uniquely upregulated and represents a therapeutic target in acute myeloid leukemia with chromosome 3q rearrangements 2021 ·Haematologica ·Sarah Grasedieck, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Frank G. Rücker, Konstanze Döhner, Tobias Herold, Jonathan R. Pollack, Lars Bullinger, A. MAUREEN ROUHI, Florian Kuchenbauer	8
4	Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia 2020 ·Science ·Hannah J. Uckelmann, (unknown), Eric Wong, Charlie Hatton, Hugh Giovinazzo, Jayant Y. Gadrey, Andrei V. Krivtsov, Frank G. Rücker, Konstanze Döhner, Gerard M. McGeehan, Ross L. Levine, Lars Bullinger, George S. Vassiliou, Scott A. Armstrong	152
5	Molecular Landscape and Prognostic Impact of FLT3 Internal Tandem Duplication Insertion Site in Acute Myeloid Leukemia (AML): Results from the Ratify Study (Alliance 10603) 2020 ·Frank G. Rücker	1
6	Analysis of the CDK4/6 Cell Cycle Pathway in Leiomyosarcomas as a Potential Target for Inhibition by Palbociclib 2019 ·Sarcoma ·(unknown), Ralf Marienfeld, (unknown), Kevin Mellert, Adrian von Witzleben, Silke Brüderlein, Mathias Wittau, Alexandra von Baer, Markus Schultheiß, Regine Mayer‐Steinacker, Frank G. Rücker, Peter Mӧller, Lars Bullinger, Thomas F.E. Barth	11
7	Clinical implications of subclonal TP53 mutations in acute myeloid leukemia 2018 ·Haematologica ·Katharina Prochazka, Gudrun Pregartner, Frank G. Rücker, Ellen Heitzer, (unknown), Albert Wölfler, Armin Zebisch, Andrea Berghold, Konstanze Döhner, Heinz Sill	64
8	Haploinsufficiency of ETV6 and CDKN1B in patients with acute myeloid leukemia and complex karyotype 2014 ·BMC Genomics ·Simone Feurstein, Frank G. Rücker, Lars Bullinger, Winfried Hofmann, Georgi Manukjan, Gudrun Göhring, Ulrich Lehmann, Michael Heuser, Arnold Ganser, Konstanze Döhner, Brigitte Schlegelberger, Doris Steinemann	21
9	Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance 2012 ·Leukemia ·Frank G. Rücker, (unknown), Sibylle Cocciardi, H. Kett, Richard F. Schlenk, (unknown), Christian Langer, J Krauter, Stefan Fröhling, Brigitte Schlegelberger, Arnold Ganser, Peter Lichter, Thorsten Zenz, Hartmut Döhner, Konstanze Döhner, Lars Bullinger	40
10	Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing 2012 ·Blood ·Anna Dolnik, Julia C. Engelmann, Maren Scharfenberger‐Schmeer, (unknown), (unknown), (unknown), (unknown), Jan Krönke, Michael W.M. Kühn, Peter Paschka, Sabine Käyser, Stephan Wolf, Verena I. Gaidzik, Richard F. Schlenk, Frank G. Rücker, Hartmut Döhner, Claudio Lottaz, Konstanze Döhner, Lars Bullinger	112
11	Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia 2011 ·Haematologica ·(unknown), Sandrine Sander, (unknown), Kyle M. Lang, Michael Bauer, Frank G. Rücker, Hans A. Kestler, Richard F. Schlenk, Hartmut Döhner, Karlheinz Holzmann, Konstanze Döhner, Lars Bullinger	36
12	SEURAT: Visual analytics for the integrated analysis of microarray data 2010 ·BMC Medical Genomics ·Alexander Gribov, Martin Sill, (unknown), Frank G. Rücker, Konstanze Döhner, Lars Bullinger, Axel Benner, Antony Unwin	121
13	Molecular characterization of AML with ins(21;8)(q22;q22q22) reveals similarity to t(8;21) AML 2010 ·Genes Chromosomes and Cancer ·Frank G. Rücker, Lars Bullinger, Alexander Gribov, Martin Sill, Richard F. Schlenk, Peter Lichter, Hartmut Döhner, Konstanze Döhner	6
14	Induction Therapy with Idarubicin and Etoposide Combined with Sequential or Concurrent Azacitidine In Patients with High-Risk Acute Myeloid Leukemia: Pilot-Phase of the AMLSG 12-09 Study 2010 ·Blood ·Frank G. Rücker, Stephan Stilgenbauer, Martin Bommer, Daniela Späth, Silja Mack, Konstanze Döhner, Hartmut Döhner, Richard F. Schlenk	1
15	Results of a multicenter phase II trial for older patients with c‐Kit‐positive acute myeloid leukemia (AML) and high‐risk myelodysplastic syndrome (HR‐MDS) using low‐dose Ara‐C and Imatinib 2007 ·Cancer ·Florian H. Heidel, Jörge E. Cortes, Frank G. Rücker, Walter E. Aulitzky, Laurie Letvak, Thomas Kindler, Christoph Huber, Hartmut Döhner, Hagop M. Kantarjian, Thomas Fischer	36
16	The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis 2007 ·Journal of Clinical Investigation ·Claudia Scholl, Dimple Bansal, Konstanze Döhner, Karina Eiwen, Brian J.P. Huntly, Benjamin H. Lee, Frank G. Rücker, Richard F. Schlenk, Lars Bullinger, Hartmut Döhner, D. Gary Gilliland, Stefan Fröhling	98
17	Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia 2007 ·Blood ·Lars Bullinger, Frank G. Rücker, (unknown), Juan Du, Claudia Scholl, Sandrine Sander, Andrea Corbacioglu, Claudio Lottaz, Jürgen Krauter, Stefan Fröhling, Arnold Ganser, Richard F. Schlenk, Konstanze Döhner, Jonathan R. Pollack, Hartmut Döhner	85
18	Molecular profiling reveals myeloid leukemia cell lines to be faithful model systems characterized by distinct genomic aberrations 2006 ·Leukemia ·Frank G. Rücker, Sandrine Sander, Konstanze Döhner, Hartmut Döhner, Jonathan R. Pollack, Lars Bullinger	31
19	Disclosure of Candidate Genes in Acute Myeloid Leukemia With Complex Karyotypes Using Microarray-Based Molecular Characterization 2006 ·Journal of Clinical Oncology ·Frank G. Rücker, Lars Bullinger, Carsten Schwäenen, Daniel B. Lipka, Swen Weßendorf, Stefan Fröhling, Martin Bentz, Simone Miller, Claudia Scholl, Richard F. Schlenk, Bernhard Radlwimmer, Hans A. Kestler, Jonathan R. Pollack, Peter Lichter, Konstanze Döhner, Hartmut Döhner	107
20	CD95 Ligand (CD95L) in Normal Human Lymphoid Tissues 1999 ·American Journal Of Pathology ·Jörn Sträter, Sara M Mariani, Henning Walczak, Frank G. Rücker, Frank Leithäuser, Peter H. Krammer, (unknown)	33

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact